Based on 2 analysts giving stock ratings to Theriva Biologics Inc in the past month.
In the current month, TOVX has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TOVX average Analyst price target in the last month is 4.000.
Based on analysts' estimates, TOVX EPS is projected to reach -0.060 in FY2026Q4, following reported EPS of -0.030 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.03, while Theriva Biologics IncTOVX's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.06.